Author archives: a1095400
Search news stories
Enter a keyword to search news.
Meet our researchers: Dr Adrienne Sullivan
As Group Leader of the Development and Epigenetics Laboratory at SAiGENCI and the Adelaide Centre for Epigenetics, Dr Sullivan studies epigenetics, the molecular system that controls how genes are switched on and off without changing the DNA code itself.
[Read more about Meet our researchers: Dr Adrienne Sullivan ]
Fiona Hemstock: Honouring a legacy through hope and discovery
For SAiGENCI supporter Fiona Hemstock, giving is deeply personal — a way to honour a remarkable legacy while helping shape a future where cancer treatment is kinder, safer, and more effective.
[Read more about Fiona Hemstock: Honouring a legacy through hope and discovery]
A gentler future for radiation treatment
For many people facing cancer, radiation therapy is a vital part of their treatment. But for most patients, it also brings an uncomfortable and sometimes painful side effect — skin damage caused by radiation.
Switching off “jumping genes” to outsmart resistant breast cancer
Breast cancer is the most commonly diagnosed cancer among women in Australia, with more than 21,000 new cases each year. Around 70 per cent of these cancers are oestrogen receptor–positive (ER+), a type that often responds well to hormone-based treatments.
[Read more about Switching off “jumping genes” to outsmart resistant breast cancer]
Global engagement in action: Suzanne’s research exchange sparks future collaborations
Suzanne Rajesh, a PhD student in the Prostate Cancer Research Group at the South Australian immunoGENomics Cancer Institute (SAiGENCI), is advancing the search for new biomarkers in prostate cancer through international collaboration.
Breakthroughs in ubiquitin biology highlighted at inaugural Australian Ubiquitin Summit
The inaugural Lorne Ubiquitin Australian Ubiquitin Summit 2025, held from 16-20 of November in Lorne, Victoria, brought together leading scientists, clinicians, and industry innovators to explore one of the most dynamic areas of modern biomedical research: ubiquitin biology and targeted protein degradation (TPD).
SAiGENCI welcomes 2025/26 Summer Research cohort
SAiGENCI kicked off it’s 2025/26 summer research program with a morning tea last week, celebrating the arrival of this year’s students.
[Read more about SAiGENCI welcomes 2025/26 Summer Research cohort]
Viertel Fellowship for innovative cancer epigentic leader
University of Adelaide cancer epigenetics and 3D genome biology expert Dr Joanna Achinger-Kawecka has been awarded a 2025 Sylvia and Charles Viertel Senior Medical Research Fellowship.
[Read more about Viertel Fellowship for innovative cancer epigentic leader]
Professor Jose Polo elected Fellow of the Australian Academy of Health and Medical Sciences (AAHMS)
SAiGENCI are proud to announce Professor Jose Polo has been elected as Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
Outcome of the inaugural Professor Abdi Cancer Research Funding Initiative
SAiGENCI is thrilled to share the exciting outcome of our inaugural Professor Abdi Cancer Research Funding Initiative. This initiative is made possible by the generous donation from Professor Abdi, and the tremendous effort of everyone who have contributed to our philanthropic activities. This round drew a large number of outstanding applications, making the selection process highly competitive.
[Read more about Outcome of the inaugural Professor Abdi Cancer Research Funding Initiative]